
KeyHealth to appeal order to fund teenager’s rare-disease treatment
The Appeals Committee found KeyHealth had not shown its proposed care was an effective alternative and ordered it to fund ravulizumab in full.

The Appeals Committee found KeyHealth had not shown its proposed care was an effective alternative and ordered it to fund ravulizumab in full.

In 2022, the industry saw a net income of R2.57 billion – down from R12.18bn in 2021 – and faced an operating deficit of R6.155bn, the largest in 23 years.

None of the events stipulated for triggering the termination of the agreement had taken place, Supreme Court of Appeal finds.

The Gauteng High Court has lifted the curatorship of KeyHealth Medical Scheme, and the board of trustees was authorised to manage the scheme from 5 April. Council for Medical Schemes (CMS) chief executive […]

In 2020, the KeyHealth Medical Scheme was placed under provisional curatorship as a result of certain corporate governance irregularities. “The journey of restoring governance at KeyHealth Medical Scheme continues,” according to the Council […]